These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 2780003

  • 21. A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension.
    Schachar RA, Raber S, Courtney R, Zhang M.
    Curr Eye Res; 2011 Sep; 36(9):809-17. PubMed ID: 21851167
    [Abstract] [Full Text] [Related]

  • 22. The ocular effects of prostaglandins and the therapeutic potential of a new PGF2 alpha analog, PhXA41 (latanoprost), for glaucoma management.
    Bito LZ, Stjernschantz J, Resul B, Miranda OC, Basu S.
    J Lipid Mediat; 1993 Sep; 6(1-3):535-43. PubMed ID: 8358014
    [Abstract] [Full Text] [Related]

  • 23. Effects of topically applied prostaglandin F2 alpha on normotensive human eyes.
    Erkiliç K, Ekinciler OF, Mirza GE, Doğan H, Cağil N.
    Ophthalmic Res; 1996 Sep; 28(6):351-5. PubMed ID: 9032793
    [Abstract] [Full Text] [Related]

  • 24. PGF2 alpha/pilocarpine interactions on IOP and accommodation in monkeys.
    Millar JC, Kaufman PL.
    Exp Eye Res; 1995 Dec; 61(6):677-83. PubMed ID: 8846839
    [Abstract] [Full Text] [Related]

  • 25. The effects of unoprostone isopropyl 0.12% and timolol maleate 0.5% on diurnal intraocular pressure.
    Stewart WC, Stewart JA, Kapik BM.
    J Glaucoma; 1998 Dec; 7(6):388-94. PubMed ID: 9871860
    [Abstract] [Full Text] [Related]

  • 26. In-vivo activity and enzymatic hydrolysis of novel prostaglandin F2 alpha prodrugs in ocular tissues.
    Woodward DF, Chan MF, Cheng-Bennett A, Wheeler LA, Chen G, Burke JA, Kharlamb A, Lai RK, Shan T.
    Exp Eye Res; 1996 Oct; 63(4):411-23. PubMed ID: 8944548
    [Abstract] [Full Text] [Related]

  • 27. Effect of topical prostaglandin PGA2, PGA2 isopropyl ester, and PGF2 alpha isopropyl ester on intraocular pressure in normotensive and glaucomatous canine eyes.
    Gum GG, Kingsbury S, Whitley RD, Garcia A, Gelatt KN.
    J Ocul Pharmacol; 1991 Oct; 7(2):107-16. PubMed ID: 1919268
    [Abstract] [Full Text] [Related]

  • 28. A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension.
    Aung T, Chew PT, Yip CC, Chan YH, See JL, Khng CG, Hoh ST, Ng LH, Lee HM.
    Am J Ophthalmol; 2001 May; 131(5):636-42. PubMed ID: 11336940
    [Abstract] [Full Text] [Related]

  • 29. Effects of prostaglandins F2 alpha, A2, and their esters in glaucomatous monkey eyes.
    Wang RF, Camras CB, Lee PY, Podos SM, Bito LZ.
    Invest Ophthalmol Vis Sci; 1990 Nov; 31(11):2466-70. PubMed ID: 2243010
    [Abstract] [Full Text] [Related]

  • 30. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group.
    Camras CB.
    Ophthalmology; 1996 Jan; 103(1):138-47. PubMed ID: 8628544
    [Abstract] [Full Text] [Related]

  • 31. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study.
    Mishima HK, Masuda K, Kitazawa Y, Azuma I, Araie M.
    Arch Ophthalmol; 1996 Aug; 114(8):929-32. PubMed ID: 8694726
    [Abstract] [Full Text] [Related]

  • 32. Ocular Hypotensive Effect of ONO-9054, an EP3/FP Receptor Agonist: Results of a Randomized, Placebo-controlled, Dose Escalation Study.
    Harris A, Ward CL, Rowe-Rendleman CL, Ouchi T, Wood A, Fujii A, Serle JB.
    J Glaucoma; 2016 Oct; 25(10):e826-e833. PubMed ID: 27300645
    [Abstract] [Full Text] [Related]

  • 33. Additive ocular hypotensive effect of latanoprost and acetazolamide. A short-term study in patients with elevated intraocular pressure.
    Rulo AH, Greve EL, Hoyng PF.
    Ophthalmology; 1997 Sep; 104(9):1503-7. PubMed ID: 9307648
    [Abstract] [Full Text] [Related]

  • 34. Intraocular pressure fluctuations in response to the water-drinking provocative test in patients using latanoprost versus unoprostone.
    Susanna R, Medeiros FA, Vessani RM, Giampani J, Borges AS, Jordão ML.
    J Ocul Pharmacol Ther; 2004 Oct; 20(5):401-10. PubMed ID: 15650515
    [Abstract] [Full Text] [Related]

  • 35. Maintained intraocular pressure reduction with once-a-day application of a new prostaglandin F2 alpha analogue (PhXA41). An in-hospital, placebo-controlled study.
    Rácz P, Ruzsonyi MR, Nagy ZT, Bito LZ.
    Arch Ophthalmol; 1993 May; 111(5):657-61. PubMed ID: 8489449
    [Abstract] [Full Text] [Related]

  • 36. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost.
    Gandolfi SA, Cimino L.
    Ophthalmology; 2003 Mar; 110(3):609-14. PubMed ID: 12623831
    [Abstract] [Full Text] [Related]

  • 37. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups.
    Camras CB, Alm A, Watson P, Stjernschantz J.
    Ophthalmology; 1996 Nov; 103(11):1916-24. PubMed ID: 8942890
    [Abstract] [Full Text] [Related]

  • 38. A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 and 4 Weeks of Twice-Daily Ocular Trabodenoson in Adults with Ocular Hypertension or Primary Open-Angle Glaucoma.
    Myers JS, Sall KN, DuBiner H, Slomowitz N, McVicar W, Rich CC, Baumgartner RA.
    J Ocul Pharmacol Ther; 2016 Oct; 32(8):555-562. PubMed ID: 27002298
    [Abstract] [Full Text] [Related]

  • 39. Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study.
    Lopes JF, Hubatsch DA, Amaris P.
    BMC Ophthalmol; 2015 Nov 12; 15():166. PubMed ID: 26563363
    [Abstract] [Full Text] [Related]

  • 40. A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6 month data.
    Nordmann JP, Mertz B, Yannoulis NC, Schwenninger C, Kapik B, Shams N, Unoprostone Monotherapy Study Group-EU.
    Am J Ophthalmol; 2002 Jan 12; 133(1):1-10. PubMed ID: 11755834
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.